Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 226 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... April 16, 2021 Load more HOT NEWS Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... For Early-Stage Lung Cancer, Nivolumab and Chemo before Surgery Proves Effective 4 Ways to Avoid Comparing Yourself to Others on Social Media... PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
